CBC-Backed Hasten Biopharmaceutical Announces Acquisition of 14 Celltrion Legacy Products
Acquiring Company
Hasten Biopharmaceutic Ltd
Acquired Company
Celltrion
IncheonBiotechnologyHealth CareManufacturingBiotechnologyTherapeuticsPharmaceuticalBiopharmaDescription
CBC Group, Asia's largest healthcare-dedicated asset management firm, has announced the successful acquisition by its controlled portfolio company, Hasten Biopharmaceutical, of the asset rights of 14 branded products across Pan-Asia countries and regions from Celltrion, a South Korean biopharmaceutical company. This strategic deal leverages CBC's hands-on 'investor-operator' approach and Hasten's expansion trajectory across Pan-Asia.
Quick answer
Hasten Biopharmaceutic Ltd is acquiring Celltrion, announced July 2, 2024.
- How much did Hasten Biopharmaceutic Ltd pay for Celltrion?
- The deal value was not disclosed.
- What does Hasten Biopharmaceutic Ltd do?
- Hasten Biopharmaceutic Company Limited ("Hasten") is an innovation-driven pharmaceutical company.
- Where are Hasten Biopharmaceutic Ltd and Celltrion based?
- Celltrion is based in Incheon, Seoul, South Korea.
- Who are the decision-makers at Hasten Biopharmaceutic Ltd?
- Fundz holds 1 contact at Hasten Biopharmaceutic Ltd. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie finalizes acquisition of Landos Biopharma, Inc. to advance treatment for ulcerative colitis and Crohn's disease (May 23, 2024)
- Cycle Pharmaceuticals proposes to acquire Vanda Pharmaceuticals for $8.00 per share (June 6, 2024)
- Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease (August 16, 2024)
- Ligand Pharmaceuticals to acquire APEIRON Biologics AG to enhance royalty portfolio (July 8, 2024)
- Lilly completes acquisition of Morphic to enhance immunology pipeline (July 8, 2024)
- Sudeep Pharma promoters regain 100% ownership by acquiring 50% shares from JRS Pharma (July 8, 2024)
Who to call at Hasten Biopharmaceutic Ltd, and when
When Hasten Biopharmaceutic Ltd changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Hasten Biopharmaceutic Ltd raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Hasten Biopharmaceutic Ltd, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Hasten Biopharmaceutic Ltd. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Hasten Biopharmaceutic Ltd makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Celltrion?
Celltrion was acquired by Hasten Biopharmaceutic Ltd. The deal was reported on July 1, 2024. Hasten Biopharmaceutic Company Limited ("Hasten") is an innovation-driven pharmaceutical company. Hasten Biopharmaceutic Ltd is privately held and operates in Biotechnology.
When did Hasten Biopharmaceutic Ltd acquire Celltrion?
Hasten Biopharmaceutic Ltd's acquisition of Celltrion was reported on July 1, 2024. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Celltrion do?
Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. It is privately held, operating in Manufacturing, and is based in Incheon.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.